From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With Human Immunodeficiency Virus in Low- and Middle-Income Settings.
Jennifer Manne-GoehlerMohammed K AliDavid FloodVincent C MarconiWillem D F VenterMark J SiednerPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found a 35% reduction in major adverse cardiovascular events for people with human immunodeficiency virus who received daily pitavastatin. However, how this evidence will change practice is far from certain. Here, we outline evidence gaps and political and healthcare delivery challenges that will need to be addressed for REPRIEVE to offer public health benefits in low- and middle-income countries.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hepatitis c virus
- hiv infected
- cardiovascular events
- healthcare
- hiv positive
- public health
- hiv aids
- randomized controlled trial
- cardiovascular disease
- primary care
- physical activity
- hiv testing
- type diabetes
- south africa
- social media
- men who have sex with men
- health information
- adverse drug
- quality improvement